No prior CVD group (n = 1013) | Prior CVD group (n = 4996) | |||||
---|---|---|---|---|---|---|
Odds ratio | 95 % CI | P value | Odds ratio | 95 % CI | P value | |
Region (Europe as reference group) | 0.475 | 0.316; 0.704 | <0.001 | 0.762 | 0.647; 0.896 | 0.001 |
Age (per year) | 1.015 | 0.981; 1.050 | 0.393 | 1.032 | 1.020; 1.043 | <0.001 |
Sex (male as reference group) | 0.485 | 0.169; 1.271 | 0.148 | 0.834 | 0.685; 1.011 | 0.065 |
Diabetes duration (per year) | 0.976 | 0.951; 1.000 | 0.055 | 0.976 | 0.967; 0.986 | <0.001 |
Race (white as reference group) | ||||||
Asian | 0.970 | 0.139; 4.258 | 0.598 | 0.257; 1.223 | ||
Black | 1.691 | 0.672; 4.244 | 0.718 | 1.069 | 0.780; 1.452 | 0.266 |
Other | 1.358 | 0.195; 6.005 | 0.604 | 0.258; 1.248 | ||
Pre-trial diabetes treatment (none, diet as reference group) | ||||||
Insulin + OADs | 1.080 | 0.475; 2.710 | 0.800 | 0.586; 1.102 | ||
Insulin only | 0.956 | 0.272; 3.215 | 0.543 | 0.532 | 0.349; 0.805 | <0.001 |
OADs only | 1.365 | 0.629; 3.312 | 1.248 | 0.930; 1.693 | ||
BMI (18–25 as reference group) (kg/m2) | ||||||
25–30 | 0.628 | 0.286; 1.446 | 1.220 | 0.871; 1.730 | ||
30–35 | 0.788 | 0.369; 1.780 | 0.235 | 1.010 | 0.723; 1.427 | 0.049 |
35–40 | 0.619 | 0.273; 1.464 | 1.036 | 0.729; 1.488 | ||
>40 | 1.082 | 0.476; 2.575 | 0.824 | 0.561; 1.219 | ||
Creatinine, per μmol/L | 0.966 | 0.915; 1.015 | 0.179 | 0.998 | 0.993; 1.002 | 0.288 |
ACR, per mg/mmol | 1.002 | 0.997; 1.005 | 0.421 | 1.000 | 0.999; 1.002 | 0.471 |
eGFR, per mL/min/1.73 m2 | 0.967 | 0.931; 1.000 | 0.048 | 0.992 | 0.986; 0.998 | 0.007 |